Myositis autoantibodies in Korean patients with inflammatory myositis: Anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis

BMC Musculoskeletal Disorders

Volumn 11, Issue , 2010, Pages

  Kang, Eun Ha ^a   Nakashima, Ran ^b   Mimori, Tsuneyo ^b   Kim, Jinhyun ^c   Lee, Yun Jong ^a,c   Lee, Eun Bong ^c   Song, Yeong Wook ^c  

^a Seoul National University Bundang Hospital   (South Korea)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOACYL TRANSFER RNA SYNTHETASE ANTIBODY; AUTOANTIBODY; MI2 ANTIBODY; POLYPEPTIDE ANTIBODY; SIGNAL RECOGNITION PARTICLE ANTIBODY; UNCLASSIFIED DRUG; PEPTIDE;

ADULT; ARTICLE; CANCER SURVIVAL; CLINICALLY AMYOPATHIC DERMATOMYOSITIS; DERMATOMYOSITIS; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HEALTH SURVEY; HUMAN; IMMUNOPRECIPITATION; INTERSTITIAL LUNG DISEASE; KOREA; MAJOR CLINICAL STUDY; MALE; NEOPLASM; POLYMYOSITIS; SENSITIVITY AND SPECIFICITY; AGED; BLOOD; ETHNOLOGY; IMMUNOLOGY; MIDDLE AGED; MOLECULAR WEIGHT; MYOSITIS; PATHOLOGY; SOUTH KOREA;

ADULT; AGED; AUTOANTIBODIES; DERMATOMYOSITIS; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MOLECULAR WEIGHT; MYOSITIS; PEPTIDES; REPUBLIC OF KOREA;

EID: 77957135967     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-11-223     Document Type: Article

References (30)

1. Etiology and pathogenesis of inflammatory muscle disease. K Nagaraju PH Plotz FW Miller, Rheumatology New York: Mosby, Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, 3 2003 2 1523 1536
2. Interstitial lung disease in polymyositis and dermatomyositis. I Marie E Hachulla P Chérin S Dominique PY Hatron MF Hellot B Devulder S Herson H Levesque H Courtois, Arthritis Rheum 2002 47 614 622 10.1002/art.10794 12522835
3. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. I Marie E Hachulla PY Hatron MF Hellot H Levesque B Devulder H Courtois, J Rheumatol 2001 28 2230 2237 11669162
4. Amyopathic dermatomyositis (dermatomyositis siné myositis). Presentation of six new cases and review of the literature. RL Euwer RD Sontheimer, J Am Acad Dermatol 1991 24 959 966 10.1016/0190-9622(91)70153-S 1869684
5. Systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. P Gerami JM Schope L McDonald HW Walling RD Sontheimer, J Am Acad Dermatol 2006 54 597 561 10.1016/j.jaad.2005.10.041 16546580
6. Therapeutic efficacy of cyclosporin A in four cases of amyopathic dermatomyositis with rapidly progressive interstitial pneumonia. Y Ozawa D Kurosaka T Yokoyama N Tajima, Ryumachi 2000 40 798 809 11215158
7. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. EH Kang EB Lee KC Shin CH Im DH Chung SK Han YW Song, Rheumatology (Oxford) 2005 44 1282 1286 10.1093/rheumatology/keh723 15972351
8. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. LA Love RL Leff DD Fraser IN Targoff M Dalakas PH Plotz FW Miller, Medicine (Baltimore) 1991 70 360 374 1659647
9. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. S Sato M Hirakata M Kuwana A Suwa S Inada T Mimori T Nishikawa CV Oddis Y Ikeda, Arthritis Rheum 2005 52 1571 1576 10.1002/art.21023 15880816
10. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. K Kaji M Fujimoto M Hasegawa M Kondo Y Saito K Komura T Matsushita H Orito Y Hamaguchi K Yanaba M Itoh Y Asano M Seishima F Ogawa S Sato K Takehara, Rheumatology (Oxford) 2007 46 25 28 10.1093/rheumatology/kel161 16728436
11. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. IN Targoff G Mamyrova EP Trieu O Perurena B Koneru TP O'Hanlon FW Miller LG Rider Childhood Myositis Heterogeneity Study Group; International Myositis Collaborative Study Group, Arthritis Rheum 2006 54 3682 3689 10.1002/art.22164 17075819
12. Association of distinct clinical subsets with myositis-specific autoantibodies towards anti-155/140-kDa polypeptides, anti-140-kDa polypeptides, and anti-aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-sectional study. K Fujikawa A Kawakami K Kaji M Fujimoto S Kawashiri N Iwamoto T Aramaki K Ichinose M Tamai M Kamachi H Nakamura H Ida T Origuchi H Ishimoto H Mukae M Kuwana S Kohno K Takehara S Sato K Eguchi, Scand J Rheumatol 2009 38 263 267 10.1080/03009740802687455 19444719
13. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. R Nakashima Y Imura S Kobayashi N Yukawa H Yoshifuji T Nojima D Kawabata K Ohmura T Usui T Fujii K Okawa T Mimori, Rheumatology (Oxford) 2010 49 433 440 10.1093/rheumatology/ kep375 20015976
14. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. H Chinoy N Fertig CV Oddis WE Ollier RG Cooper, Ann Rheum Dis 2007 66 1345 1349 10.1136/ard.2006.068502 17392346
15. Cancer-associated myositis and anti-p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy. E Trallero-Aragus M Labrador-Horrillo A Selva-O'Callaghan MA Martínez X Martínez- Gámez E Palou JL Rodriguez-Sanchez M Vilardell-Tarrés, Medicine (Baltimore) 2010 89 47 52 10.1097/MD.0b013e3181ca14ff 20075704
16. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. H Gunawardena LR Wedderburn J North Z Betteridge J Dunphy H Chinoy JE Davidson RG Cooper NJ McHugh Juvenile Dermatomyositis Research Group UK, Rheumatology (Oxford) 2008 47 324 328 10.1093/rheumatology/ kem359 18238791
17. In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. H Chinoy F Salway S John N Fertig BD Tait CV Oddis WE Ollier RG Cooper UK Adult Onset Myositis Immunogenetic Collaboration (AOMIC), Arthritis Res Ther 2006 8 13 10.1186/ar1862 16507114
18. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. TP O'Hanlon DM Carrick IN Targoff FC Arnett JD Reveille M Carrington X Gao CV Oddis PA Morel JD Malley K Malley EA Shamim LG Rider SJ Chanock CB Foster T Bunch PJ Blackshear PH Plotz LA Love FW Miller, Medicine (Baltimore) 2006 85 111 127 10.1097/01.md.0000217525.82287.eb 16609350
19. Polymyositis and dermatomyositis (first of two parts). A Bohan JB Peter, N Engl J Med 1975 292 344 347 10.1056/NEJM197502132920706 1090839
20. Genetic risk and protective factors for idiopathic inflammatory myopathy in Koreans and American whites: a tale of two loci. LG Rider E Shamim S Okada JP Pandey IN Targoff TP O'Hanlon HA Kim YS Lim H Han YW Song FW Miller, Arthritis Rheum 1999 42 1285 1290 10.1002/1529-0131(199906)42:6<1285::AID-ANR28>3.0. CO;2-1 10366124
21. Aseptic meningitis in mixed connective tissue disease: Cytokine and anti-U1RNP antibodies in cerebrospinal fluids from two different cases. Y Fujita T Fujii R Nakashima M Tanaka T Mimori, Mod Rheumatol 2008 18 184 188 10.1007/s10165-008-0022-7 18283524
22. Pneumomediastinum and subcutaneous emphysema associated with fatal interstitial pneumonia in dermatomyositis. Y Nagai O Ishikawa Y Miyachi, J Dermatol 1997 24 482 484 9267111
23. Successful combined therapy of cyclophosphamide and cyclosporine for acute exacerbated interstitial pneumonia associated with dermatomyositis. F Tanaka T Origuchi K Migita M Tominaga A Kawakami Y Kawabe K Eguchi, Intern Med 2000 39 428 430 10.2169/internalmedicine.39.428 10830189
24. Successful treatment of dermatomyositis-related rapidly progressive interstitial pneumonitis with sequential oral cyclophosphamide and azathioprine. CC Mok CH To ML Szeto, Scand J Rheumatol 2003 32 181 183 10.1080/ 03009740310002542 12892257
25. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. H Kameda H Nagasawa H Ogawa N Sekiguchi H Takei M Tokuhira K Amano T Takeuchi, J Rheumatol 2005 32 1719 1726 16142867
26. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. S Sato K Hoshino T Satoh T Fujita Y Kawakami T Fujita M Kuwana, Arthritis Rheum 2009 60 2193 2200 10.1002/art.24621 19565506
27. Malignancy in the setting of the anti-synthetase syndrome. A Rozelle S Trieu L Chung, J Clin Rheumatol 2008 14 285 288 10.1097/RHU.0b013e31817d116f 18664993
28. Cancer-associated myositis in the presence of anti-Jo1 autoantibodies and the antisynthetase syndrome. D Legault J McDermott AM Crous-Tsanaclis G Boire, J Rheumatol 2008 35 169 171 18176990
29. Autoantibodies to transcriptional intermediary factor 1-gamma (TIF-g) in dermatomyositis. IN Targoff EP Trieu M Levy-Neto T Prasertsuntarasai FW Miller, Arthritis Rheum 2006 54 518 10.1002/art.22164 (Pubitemid 44737181)
30. Anti-MDA5 and anti-TIF1-{gamma} antibodies have clinical significance for patients with dermatomyositis. K Hoshino Y Muro K Sugiura Y Tomita R Nakashima T Mimori, Rheumatology (Oxford) 2010 49 1726 1733 10.1093/rheumatology/keq153 20501546